The Crucial Problem of ASCVD: Can New Therapeutic Options Resolve It? | eMedEvents

Page 1

Primary Care Network (PCN) Presents

The Crucial Problem of ASCVD: Can New Therapeutic Options Resolve It? Cardiology

CME 1.00

Duration:

Faculty:

Unknown

Alan S. Brown, James A. Underberg

The Crucial Problem of ASCVD: Can New Therapeutic Options Resolve It?

 Share Activity

 Print Activity

is organized by Primary Care Network (PCN).

Organizer(s) Release / Expiration Date: This internet, enduring activity (audio/slides) will be available for one year, beginning January 30, 2019 through January 30, 2020. Create PDF in your applications with the Pdfcrowd HTML to PDF API

Chat with us

Primary Care Network (PCN) View Organizer Details Type your message here

PDFCROWD


Target Audience:

 Conference Website

The intended audiences for this initiative include family medicine practitioners, primary care providers, lipidologists, clinical cardiologists, internists, and other healthcare professionals tasked with refining and updating clinical decision-making practices and establishing partnerships with ASCVD patients to improve clinical outcomes.

Help 417-877-6668, (417) 8413633

Accreditation/Designation Statements:

 education@primarycaren

Boston University School of Medicine designates this enduring material

etwork.org

for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Related Books

American Board of Internal Medicine’s (ABIM) Maintenance Of Certification (MOC): Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0

USD $39.95

USD $279.99

USD $56.99

Medical Knowledge MOC point in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Create PDF in your applications with the Pdfcrowd HTML to PDF API

PDFCROWD


American Academy of Family Physicians (AAFP): This Enduring Material activity, THE CRUCIAL PROBLEM OF ASCVD, Can New Therapeutic Options Resolve It?, has been reviewed and is acceptable for up to 1.00 Prescribed credit by the American Academy of Family Physicians. AAFP certification begins 01/30/2019. Term of approval is for one year from this date. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Program Overview: Clinically evident atherosclerotic cardiovascular disease (ASCVD) is a leading cause of death and mortality in the US, and elevated serum LDL-C is a widely-recognized cardiovascular disease (CVD) risk factor. Since hypercholesterolemia is a major driver of ASCVD, lipid-lowering therapies (mainly statins) are the primary approach to lower low-density lipoprotein cholesterol (LDL-C). Unfortunately, intensive statin therapy lowers CVD risk by only ~50%, leaving many patients at excessively high residual CVD risk with no good options to reduce this risk. This activity explores the residual CVD risk that ASCVD patients endure despite even intensive statin therapy. The education will also examine the possibility of additional CVD risk reduction by adding lipid-lowering therapies to statins, including the use of add-on therapies (ezetimibe and

Create PDF in your applications with the Pdfcrowd HTML to PDF API

PDFCROWD


recent PCSK9 inhibitors) to improve clinical outcomes in this high-risk patient population. Learning Objectives: After completing this activity, the participant should be better able to: • Evaluate the extent of residual CVD risk to which ASCVD patients are exposed, and treat additional CVD risk elements as appropriate • Differentiate the clinical properties of new and emerging pharmacologic approaches to reduce LDL-C and lower CVD risk • Analyze the potential utility of new LDL-C lowering agents used in combination with statins to reduce CVD risk in patients who have ASCVD.

Intended Audience Cardiology

Activity Payment Details Activity Fee : NA REGISTER NOW

Create PDF in your applications with the Pdfcrowd HTML to PDF API

PDFCROWD


Rate this CME (Min 1 - Max 5) Duration:



Fee and



expenses: CME credits:



Program



contents: Networking:



Write Your Review SUBMIT

Reviews Given by Professionals No Reviews available. Be the first to write a review. Create PDF in your applications with the Pdfcrowd HTML to PDF API

PDFCROWD


Privacy Policy Read eMedEvents Privacy Policy

For Physicians For Speakers For Organizers Logistics Pharma & Medical Companies eMedEvents Quick Links Medical Resources

Leadership Award - 2017 Winner

Newsletter Subscription

Your Email ID

Create PDF in your applications with the Pdfcrowd HTML to PDF API

SUBMIT

PDFCROWD


Follow Us

Terms & Conditions Sitemap Security Cookies

Download App

Create PDF in your applications with the Pdfcrowd HTML to PDF API

PDFCROWD


Turn static files into dynamic content formats.

Create a flipbook
Issuu converts static files into: digital portfolios, online yearbooks, online catalogs, digital photo albums and more. Sign up and create your flipbook.